One merger contingent value right
Research scope and limits
Actual milestones, entitlement, enforceability, tax and broader classification remain open.
The filed February 3, 2026 Cycle Group and Equiniti agreement creates conditional merger consideration for covered holders and generally restricts transfer except Permitted CVR Transfers.
Second milestone requires defined FDA approval for CMT-SORD by the specified deadline and before termination. The one-time per-CVR cash amount is $0.10 without interest; holder count is the register at notice-date close of business. Parent notice/certification and funding follow the earlier of 90 days and next March 15.
The contract selects Delaware law; actual classification and enforcement under that law remain held.